For PatientsBlood Test Designed to See Very Small Traces of Cancer Recurrence, Early^1-7

Products for Patients

Our advanced tumor profiling test looks at all of the genes in your cancer cells to help match effective targeted treatments specific to your cancer.

Discover NeXT Dx

Our personalized blood test helps you determine ahead of scans: if your cancer treatment is working, if your cancer is still there after treatment, and if your cancer is likely to come back.^2-7

Discover NeXT Personal Dx

Billing & NeXT Access

Through our financial assistance program, we work with qualifying patients to reduce or eliminate their out-of-pocket costs, so they can focus on their fight against cancer.

Discover NeXT Access

Tell us your story

Every journey is unique

Tell us how Personalis® testing has been part of your story. Your experience could help others understand the difference our testing can make.

Share Your Story

References

Northcott, Josette, et al. (2024, January 6). Analytical Validation of next Personal ® , an Ultra-Sensitive Personalized Circulating Tumor DNA Assay. Oncotarget, vol. 15, pp. 200–218, www.oncotarget.com/article/28565/text/, https://doi.org/10.18632/oncotarget.28565. Accessed 19 Mar. 2024.
De Almeida Toledo, R., et al. (2024, June 4). Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials. ASCO Annual Meeting, Chicago, IL, United States.
Black, JRM, et al. (October, 2023) An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer. ESMO annual meeting, Madrid, Spain.
Garcia-Murillas, I. et al. (2025, February 04). Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. ESMO Annals of Oncology. https://www.annalsofoncology.org/article/S0923-7534(25)00053-5/
Gebhardt C., et al, (2024, April 5-10). Ultra-sensitive ctDNA detection predicts response to immune checkpoint inhibition in advanced melanoma patients. AACR Annual Meeting, San Diego, CA, United States.
Nixon A., Navarro F., et al. (2024, June) Ultra-sensitive, tumor-informed ctDNA profiling in pembrolizumab-treated gastroesophageal cancer patients reveals longitudinal ctDNA kinetics. ASCO annual meeting, Chicago, IL, United States.
Yan J., Li b., et al. (2024, April) Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune-checkpoint blockade. AACR Annual Meeting, San Diego, CA, United States.

PRO-1277-v1

We can see
what others miss.

Request Info

SEARCH

For PatientsBlood Test Designed to See Very Small Traces of Cancer Recurrence, Early1-7